Hydrochloric Acid

Hydrochloric Acid

SCHEMBL1898174

CCC(P(c1ccccc1)c1ccccc1)P(c1ccccc1)c1ccccc1.[Cl-].[Cl-].[Pd+2]

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
CYP3A4 P08684 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
MIF P14174 1/20 0.34
TP53 P04637 1/20 0.33
NOS3 P29474 1/20 0.32
NOS2 P35228 1/20 0.32
TRPA1 O75762 1/20 0.31
ESR1 P03372 2/20 0.31
ESR2 Q92731 2/20 0.31
KCNN4 O15554 1/20 0.31
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1404111 0.95 LMNA (0.37) LMNACYP3A4TDP1KDM4EGAA
Bromide SCHEMBL5527408 0.95 LMNA (0.37) LMNACYP3A4TDP1KDM4EGAA
SCHEMBL115575 0.95 LMNA (0.39) LMNACYP3A4TDP1KDM4EGAA
SCHEMBL4738364 0.93 LMNA (0.38) LMNACYP3A4TDP1KDM4EGAA
Hydrochloric Acid SCHEMBL6058391 0.93 LMNA (0.38) LMNACYP3A4TDP1KDM4EGAA
SCHEMBL14693766 0.93 LMNA (0.38) LMNACYP3A4TDP1KDM4EGAA
SCHEMBL15295495 0.93 LMNA (0.38) LMNACYP3A4TDP1KDM4EGAA
Hydrochloric Acid SCHEMBL1404110 0.91 LMNA (0.37) LMNACYP3A4TDP1KDM4EGAA
Hydrochloric Acid SCHEMBL1898172 0.91 LMNA (0.37) LMNACYP3A4TDP1KDM4EGAA
SCHEMBL7097256 0.89 LMNA (0.35) LMNACYP3A4TDP1MIFTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513054-B1 BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 JANSSEN PHARMACEUTICA NV (BE) 2016-03-09 EP disclosed
EP-2493571-B1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-07-23 EP disclosed
EP-2513054-A1 BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 Janssen Pharmaceutica, N.V. (BE) 2012-10-24 EP disclosed
EP-2493571-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2012-09-05 EP disclosed
US-20110152321-A1 BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 JANSSEN PHARMACEUTICA (BE) 2011-06-23 US disclosed
WO-2011075634-A1 BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 WO disclosed
WO-2011059731-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-05-19 WO disclosed
US-20110105562-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2011-05-05 US disclosed
US-6509476-B1 Leukotriene antagonists; antiallergens, antiinflammatory agents, and antiasthmatic agents THE UNIVERSITY OF EAST ANGLIA (GB) 2003-01-21 US disclosed
US-6160120-A Process for preparing n-benzyl indoles ELI LILLY AND COMPANY (US) 2000-12-12 US disclosed
US-5807866-A Process for preparing N-benzyl indoles THE UNIVERSITY OF EAST ANGLIA (GB) 1998-09-15 US disclosed
EP-0775694-A2 Process for preparing N-benzyl indoles University of East Anglia (GB) 1997-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152321-A1 BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 DPP4, DPP7, DPP3 LMNA 3859/4885CYP3A4 338/4885TDP1 760/4885
US-20110105562-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS DPP4, DPP3, DPP7 LMNA 3985/4885CYP3A4 602/4885TDP1 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.